Preventing Recurrent Bleeding After Eradication of Esophageal Varices

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Esophageal variceal bleeding is a severe complication of portal hypertension. Banding ligation plus non-selective beta-blockers is the current recommendation for prevention of recurrent bleeding. However, the optimal duration of use of non-selective beta-blockers is not well defined. This study aims at comparing the rebleeding rate and adverse effects in patients using or without using propranolol after eradication of esophageal varices.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Veterans General Hospital.
• Treatments: Propranolol

Criteria

Inclusion Criteria:

• Age of 20 to 80 years

• Cirrhotic patients with acute or recent esophageal variceal bleeding proven by an endoscopy

• Stable hemodynamic condition for at least 3 days after banding ligation

Exclusion Criteria:

• Hepatocellular carcinoma or other malignancy

• Stroke or active sepsis

• Chronic kidney disease under renal replacement therapy

• Contraindications to non-selective beta-blockers

• A history of non-selective beta-blockers use, sclerotherapy, banding ligation, transjugular intrahepatic porto-systemic shunt, or shunt surgery

• Serum total bilirubin >10 mg/dL

• Grade III/IV hepatic encephalopathy

• Refractory ascites

• Hepato-renal syndrome

• Pregnancy

• Severe heart failure (NYHA Fc III/IV)

• Bronchial asthma or chronic obstructive pulmonary disease

• Second or third degree atrioventricular block

• Sick sinus syndrome

• Pacemaker use

• Severe hypotension

• Refusal to participate